Detail akcie Nurexone Blgc Rg online

Business Summary: Nurexone Biologic Inc is an Israel-based company engaged primarily in the pharmaceutical sector. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The Company focuses on research and development of pharmaceutical technologies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Nurexone Biologic Inc revenues was not reported. Net loss increased 43% to $5M. Higher net loss reflects Research and development expenses increase of 63% to $2M (expense), Selling/General/Admin Expense increase of 30% to $3M (expense), Financial expenses increase from $23K to $64K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.06 to -$0.07.